The Comprehensive Systematic Review of Association of PSA Level to Clinical Stage of Carcinoma Prostat
Keywords:
Prostate-Specific Antigen (PSA), Prostate Cancer, Clinical Stage, Tumor Staging, Biomarkers, Prognosis, Systematic ReviewAbstract
Introduction: Prostate-specific antigen (PSA) is a cornerstone biomarker in prostate cancer (PCa) management, used for screening, diagnosis, staging, and monitoring treatment response. However, the precise relationship between PSA levels and clinical stage is complex and influenced by numerous factors. This systematic review synthesizes the current evidence to elucidate the association between PSA and the clinical stage of prostate carcinoma.
Methods: A comprehensive systematic review was conducted. We screened studies based on predefined criteria, including the involvement of prostate cancer patients, measurement of serum PSA levels, availability of clinical staging information, and analysis of the PSA-stage relationship. Studies were limited to human clinical studies with adequate sample sizes (≥10 patients) that examined pre-treatment PSA. Data were extracted on study design, patient characteristics, PSA measurement details, staging systems, statistical analyses, primary findings, outcomes, confounding variables, and study quality from 80 included sources.
Results: The evidence demonstrates a significant but nuanced association between PSA levels and clinical stage. Established PSA thresholds correlate with disease severity: levels <10 ng/mL are typically linked to localized disease (T1-T2), while levels >20 ng/mL consistently predict advanced/high-risk or metastatic disease (Buzzoni et al., 2015; Tombal et al., 2010). However, paradoxical findings exist, such as worse survival in high-grade patients with very low PSA (<4.0 ng/mL), indicating aggressive tumor biology with reduced PSA secretion (Kang et al., 2020). PSA kinetics (doubling time, nadir) and density (PSAD) provide enhanced prognostic value beyond absolute PSA levels. For instance, a PSA nadir <0.2 ng/mL post-treatment is strongly associated with superior overall survival (Harshman et al., 2017; Tripathi et al., 2025). The relationship is modified by tumor grade, prostate volume, race, and treatment modality. Multi-kallikrein panels improve predictive accuracy over PSA alone (Vickers et al., 2010).
Discussion: The PSA-stage relationship is context-dependent. PSA serves as a robust but imperfect predictor. Its utility is maximized when integrated with other parameters like Gleason score, imaging, and kinetics. The "PSA pyramid" concept allows for individualized screening intervals based on baseline PSA (Randazzo et al., 2015). Treatment decisions, such as radiation dose escalation or ADT duration, can be effectively guided by specific PSA thresholds and nadir values (Al-Mamgani et al., 2010; Ayoub et al., 2022).
Conclusion: PSA levels are strongly associated with the clinical stage of prostate carcinoma, providing critical prognostic information. However, interpretation must account for modifying factors like tumor grade and prostate volume. Future management should emphasize a multiparametric approach, combining PSA with advanced biomarkers and imaging for precise risk stratification and personalized treatment planning.
References
A. Al-Mamgani, W. Heemsbergen, P. Levendag, and J. Lebesque. “Subgroup Analysis of Patients with Localized Prostate Cancer Treated Within the Dutch-Randomized Dose Escalation Trial.” Radiotherapy and Oncology, 2010.
A. Benchikh, C. Savage, A. Cronin, G. Salama, A. Villers, H. Lilja, and A. Vickers. “A Panel of Kallikrein Markers Can Predict Outcome of Prostate Biopsy Following Clinical Work-up: An Independent Validation Study from the European Randomized Study of Prostate Cancer Screening, France.” BMC Cancer, 2010.
A. Nabid, M. Garant, F. Cury, André-Guy Martin, J. Bahary, P. Vavassis, S. Vass, et al. “Outcomes Comparison Using PSA Cut-Off Values Of 0.1 Or 0.2 Ng/Ml At 6 Months In Localized High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy And Radiotherapy: Prospective Data From A Phase III Trial,” 2020.
A. Nabid, N. Carrier, B. Bahoric, D. Wilke, É. Vigneault, F. Vincent, M. Brassard, et al. “Combined Risk Factors and Outcomes in High-Risk Prostate Cancer: Secondary Analysis of a Phase III Trial.” International Journal of Radiation Oncology, Biology, Physics, 2022.
A. Pollack, A. Hanlon, E. Horwitz, S. Feigenberg, and R. Uzzo. “Prostate Cancer Treated with Radiotherapy with or Without Androgen Deprivation: The Importance of the PSA Nadir Within 12 Months.” Journal of Clinical Oncology, 2004.
A. Pollack, A. Hanlon, E. Horwitz, S. Feigenberg, R. Uzzo, and G. Hanks. “Prostate Cancer Radiotherapy Dose Response: An Update of the Fox Chase Experience.” Journal of Urology, 2004.
A. Simpkin, L. Rooshenas, J. Wade, J. Donovan, J. Lane, R. M. Martin, C. Metcalfe, et al. “Development, Validation and Evaluation of an Instrument for Active Monitoring of Men with Clinically Localised Prostate Cancer: Systematic Review, Cohort Studies and Qualitative Study,” 2015.
A. Tripathi, Yu-Hui Chen, D. Jarrard, Jorge A. Garcia, R. Dreicer, Glenn Liu, M. Hussain, et al. “Impact of PSA Nadir on Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer: Final 10-Year Analysis of the ECOG-ACRIN E3805 CHAARTED Trial.” Journal of Clinical Oncology, 2025.
A. Vettenranta, T. Murtola, J. Raitanen, P. Raittinen, K. Talala, K. Taari, U. Stenman, T. Tammela, and Anssi Auvinen. “Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.” JAMA Oncology, 2021.
A. Vickers, A. Cronin, M. Roobol, C. Savage, Mari T. Peltola, K. Pettersson, P. Scardino, F. Schröder, and H. Lilja. “A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.” Clinical Cancer Research, 2010.
Andika Afriansyah, A. Hamid, C. Mochtar, and R. Umbas. “Prostate Specific Antigen (PSA) Kinetic as a Prognostic Factor in Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy: Systematic Review and Meta-Analysis.” F1000Research, 2018.
Anssi Auvinen, T. Tammela, T. Mirtti, H. Lilja, T. Tolonen, A. Kenttämies, I. Rinta-Kiikka, et al. “Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.” Journal of the American Medical Association (JAMA), 2024.
B. Tombal, K. Miller, L. Boccon‐Gibod, F. Schröder, N. Shore, E. Crawford, J. Moul, J. Jensen, Tine Kold Olesen, and B. Persson. “Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 Mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics.” European Urology, 2010.
Bin S. Teh, Bin S. Teh, G. Ayala, L. Aguilar, W. Mai, T. Timme, M. Vlachaki, et al. “Phase I-II Trial Evaluating Combined Intensity-Modulated Radiotherapy and in Situ Gene Therapy with or Without Hormonal Therapy in Treatment of Prostate Cancer-Interim Report on PSA Response and Biopsy Data.” International Journal of Radiation Oncology, Biology, Physics, 2004.
C. Buzzoni, A. Auvinen, M. Roobol, S. Carlsson, S. Moss, D. Puliti, H. D. de Koning, et al. “Metastatic Prostate Cancer Incidence and Prostate-Specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.” European Urology, 2015.
C. Ceylan, E. Gazel, I. Keles, Ö. Doluoğlu, and M. Yığman. “Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?” Current Urology, 2016.
C. Ediz, S. Akan, M. C. Temel, and O. Yilmaz. “The Importance of PSA-Density in Active Surveillance for Prostate Cancer.” Archivio Italiano Di Urologia e Andrologia, 2020.
C. Elliott, R. Shinghal, and J. Presti. “The Influence of Prostate Volume on Prostate-Specific Antigen Performance: Implications for the Prostate Cancer Prevention Trial Outcomes.” Clinical Cancer Research, 2009.
C. Hallemeier, Peixin Zhang, T. Pisansky, G. Hanks, D. McGowan, M. Roach, K. Zeitzer, et al. “Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.” International Journal of Radiation Oncology, Biology, Physics, 2019.
Chika Juliet Okwor, V. Okwor, Ijeoma A Meka, Andrew Emeka Emedoh, and Martin Nweke. “Association Between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer Following Radical Prostatectomy: A Systematic Review.” Medical Principles and Practice, 2023.
Cui-jian Zhang, Zhi-song He, and Li-qun Zhou. “[Changes in Clinical Features of Inpatients with Prostate Cancer in the Past 11 Years].” Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences, 2010.
D. Joseph, J. Denham, D. Lamb, K. Tai, S. Turner, J. Matthews, C. Atkinson, Dana Bill, M. Ebert, and A. Steigler. “2205 : The Biological Significance of Longitudinal Changes in PSA; PSA Response Signatures (PRS),” 2006.
D. Kuban, A. Pollack, E. Huang, L. Levy, L. Dong, G. Starkschall, and I. Rosen. “Hazards of Dose Escalation in Prostate Cancer Radiotherapy.” International Journal of Radiation Oncology, Biology, Physics, 2003.
D. Kuban, L. Levy, M. R. Cheung, Andrew K. Lee, Seungtaek L. Choi, S. Frank, and A. Pollack. “Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?” International Journal of Radiation Oncology, Biology, Physics, 2008.
D. Lamb, J. Denham, D. Joseph, J. Matthews, C. Atkinson, N. Spry, G. Duchesne, et al. “A Comparison of the Prognostic Value of Early PSA Test-Based Variables Following External Beam Radiotherapy, with or Without Preceding Androgen Deprivation: Analysis of Data from the TROG 96.01 Randomized Trial.” International Journal of Radiation Oncology, Biology, Physics, 2011.
E. Antonarakis, Jianqing Lin, D. Keizman, M. Carducci, and M. Eisenberger. “The Effect of Changes in PSA Kinetics on Metastasis-Free Survival (MFS) in Patients with PSA-Recurrent Prostate Cancer (PC) Treated with Nonhormonal Agents: Combined Analysis of Three Randomized Trials.” 2010.
E. Berthelet, T. Pickles, Ken Lee, Mitchell C C Liu, and P. Truong. “Long-Term Androgen Deprivation Therapy Improves Survival in Prostate Cancer Patients Presenting with Prostate-Specific Antigen Levels > 20 Ng/mL.” International Journal of Radiation Oncology, Biology, Physics, 2005.
E. Chiong, A. Wong, Y. Chan, and C. Chin. “Review of Clinical Manifestations of Biochemically-Advanced Prostate Cancer Cases.” Asian Journal of Surgery, 2005.
E. Gómez-Gómez, J. Carrasco-Valiente, A. Blanca-Pedregosa, Beatriz Barco-Sánchez, J. L. Fernandez-Rueda, Helena Molina-Abril, J. Valero-Rosa, P. Font-Ugalde, and M. J. Requena-Tapia. “European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.” Urology, 2017.
E. Kord, Basil A. Ferenczi, R. DiNatale, Adam M. Daily, H. Koenig, Jason K. Frankel, Nathan Jung, J. Flores, and Christopher C. Porter. “Are High-Risk Prostate Cancer Patients Being Treated Equally? The Impact of PSA.” Urologic Oncology, 2023.
F. Petrelli, I. Vavassori, M. Cabiddu, A. Coinu, M. Ghilardi, K. Borgonovo, V. Lonati, and S. Barni. “Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-Analysis.” Urology, 2016.
Glenn Liu, Yu‐Hui Chen, J. Kolesar, Wei Huang, R. Dipaola, M. Pins, M. Carducci, M. Stein, G. Bubley, and G. Wilding. “Eastern Cooperative Oncology Group Phase II Trial of Lapatinib in Men with Biochemically Relapsed, Androgen Dependent Prostate Cancer.” Urologic Oncology, 2013.
H. Lee, H. Jeon, B. Jeong, S. Seo, S. Jeon, H. Choi, and H. Lee. “Comparison of Pathological and Biochemical Outcomes After Radical Prostatectomy in Korean Patients with Serum PSA Ranges.” Journal of Korean Medical Science, 2015.
H. Sato, S. Narita, N. Tsuchiya, A. Koizumi, T. Nara, S. Kanda, K. Numakura, et al. “Impact of Early Changes in Serum Biomarkers Following Androgen Deprivation Therapy on Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer.” BMC Urology, 2018.
I. Paur, W. Lilleby, S. K. Bøhn, Erik Hulander, W. Klein, L. Vlatkovic, K. Axcrona, et al. “Tomato-Based Randomized Controlled Trial in Prostate Cancer Patients: Effect on PSA.” Clinical Nutrition, 2017.
J. Chung, Jiwoong Yu, Wan Song, Minyong Kang, H. Sung, H. Jeon, B. Jeong, S. Seo, H. Lee, and S. Jeon. “Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 Ng/mL).” Journal of Korean Medical Science, 2020.
J. Nikitas, Wee Loon Ong, N. Carrier, T. Romero, J. Millar, Michael L. Steinberg, M. Rettig, et al. “Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.” International Journal of Radiation Oncology, Biology, Physics, 2023.
K. Lehner, Mohamed E. Ahmed, R. Bole, Jack R. Andrews, R. Haloi, M. Bold, A. Kendi, R. Karnes, E. Kwon, and A. Bryce. “Effect of Early PSA Decline After Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting on Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate Cancer.” Journal of Clinical Oncology, 2023.
L. Harshman, Yu‐Hui Chen, Glenn Liu, M. Carducci, D. Jarrard, R. Dreicer, N. Hahn, et al. “Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.” Journal of Clinical Oncology, 2017.
L. Y. Zhu, X. Ding, T. Huang, Y. Luan, C. Guo, Y. Z. Xu, and F. Wang. “[Correlation Analysis Between Prostate Imaging Report and Data System Score and Pathological Results of Prostate Cancer].” Zhonghua Yi Xue Za Zhi, 2020.
M. Boniol, P. Autier, P. Perrin, and P. Boyle. “Variation of Prostate-Specific Antigen Value in Men and Risk of High-Grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study.” Urology, 2015.
M. Frånlund, R. Arnsrud Godtman, S. Carlsson, H. Lilja, M. Månsson, J. Stranne, and J. Hugosson. “Prostate Cancer Risk Assessment in Men with an Initial P.S.A. Below 3 Ng/mL: Results from the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.” Scandinavian Journal of Urology, 2018.
M. Hussain, C. Tangen, P. Schellhammer, E. Crawford, C. Higano, G. Wilding, A. Akdaş, E. Small, B. Donnelly, and D. Raghavan. “Absolute PSA Value After Androgen Deprivation (AD) Is a Strong Independent Predictor of Survival in New Metastatic (D2) Prostate Cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162).” Journal of Clinical Oncology, 2006.
M. King, M. Chen, and A. D'Amico. “PSA Failure as a Surrogate for All-Cause Mortality in Men with Locally Advanced Prostate Cancer,” 2020.
M. Lucia, A. Darke, P. Goodman, F. L. La Rosa, H. Parnes, L. Ford, C. Coltman, and I. Thompson. “Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention.” Cancer Prevention Research, 2008.
M. M. Gestaut, Jessica Pruszynski, and G. Swanson. “Prostate Cancer in Patients With High Prostate‐Specific Antigen Levels but Otherwise Very‐Low‐Risk Disease Behaves Like Prostate Cancer in High‐Risk Patients.” Clinical Genitourinary Cancer, 2017.
M. Randazzo, J. Beatrice, A. Huber, R. Grobholz, L. Manka, F. Chun, F. Recker, and M. Kwiatkowski. “A "PSA Pyramid" for Men with Initial Prostate-Specific Antigen ≤3 Ng/Ml: A Plea for Individualized Prostate Cancer Screening.” European Urology, 2015.
M. Randazzo, J. Beatrice, A. Huber, R. Grobholz, L. Manka, F. Recker, and M. Kwiatkowski. “MP69-04 FUTURE RISK FOR INTERMEDIATE OR HIGH RISK PROSTATE CANCER IN MEN WITH BASELINE PSA OF 1-3NG/ML AND LOW FREE-TO-TOTAL PSA-RATIO IN A PROSPECTIVE POPULATION-BASED SCREENING TRIAL (ERSPC AARAU),” 2014.
Matthew R. Smith, F. Saad, S. Oudard, N. Shore, K. Fizazi, P. Sieber, B. Tombal, et al. “Denosumab and Bone Metastasis-Free Survival in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time.” Journal of Clinical Oncology, 2013.
N. Hamidi, A. Atmaca, A. Canda, M. Keske, and A. Ardıçoğlu. “Does Extent of Prostate-Specific Antigen Fluctuation Can Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients?” Turkish Journal of Urology, 2019.
O. Offor, and S. Liauw. “PSA Halving Time of ≤2 Weeks and Post-RT PSA Nadir < 0.1 Ng/mL Are Associated With Excellent Biochemical Control for High-Risk Prostate Cancer: Implications Regarding the Need for Long-Term ADT With Dose Escalated RT,” 2012.
P. Koffer, Christina Raker, T. Dipetrillo, B. Carneiro, Anthony E Mega, Howard M. Sandler, G. Rodrigues, et al. “Evaluation of Post Radiotherapy PSA as a Prognostic and Predictive Biomarker in High Risk Prostate Cancer: A Secondary Analysis of RTOG 0521.” Journal of Clinical Oncology, 2025.
P. Kupelian, D. Kuban, H. Thames, L. Levy, E. Horwitz, Alvaro Martinez, J. Michalski, et al. “Improved Biochemical Relapse-Free Survival with Increased External Radiation Doses in Patients with Localized Prostate Cancer: The Combined Experience of Nine Institutions in Patients Treated in 1994 and 1995.” International Journal of Radiation Oncology, Biology, Physics, 2003.
P. Ravi, Lucia Kwak, J. Armstrong, V. Beckendorf, Joseph L. Chin, A. D'Amico, D. Dearnaley, et al. “Prognostic Impact of PSA Nadir (n) ≥0.1 Ng/mL Within 6 Months (m) After Completion of Radiotherapy (RT) for Localized Prostate Cancer (PCa): An Individual Patient-Data (IPD) Analysis of Randomized Trials from the ICECAP Collaborative.” Journal of Clinical Oncology, 2023.
P. Schellhammer, G. Chodak, J. Whitmore, R. Sims, M. Frohlich, and P. Kantoff. “Lower Baseline Prostate-Specific Antigen Is Associated with a Greater Overall Survival Benefit from Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial.” Urology, 2013.
R. Cheung, S. Tucker, L. Dong, and D. Kuban. “Dose-Response for Biochemical Control Among High-Risk Prostate Cancer Patients After External Beam Radiotherapy.” International Journal of Radiation Oncology, Biology, Physics, 2003.
R. Dess, Y. Sun, M. Bolla, A. Zapatero, S. Malone, A. U. Kishan, S. Roy, et al. “Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer.” International Journal of Radiation Oncology, Biology, Physics, 2021.
R. Dess, Yilun Sun, W. Jackson, N. Jairath, A. Kishan, D. Wallington, B. Mahal, et al. “Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-Term Antiandrogen Therapy in Men With Prostate Cancer.” JAMA Oncology, 2020.
R. Landy, L. Houghton, C. Berg, R. Grubb, H. Katki, and A. Black. “Risk of Prostate Cancer–Related Death Following a Low PSA Level in the PLCO Trial.” Cancer Prevention Research, 2020.
R. Martínez-Corral, P. de Pablos-Rodríguez, Celia Bardella-Altarriba, Francisco Javier Vera-Ballesteros, Arnau Abella-Serra, Victor Rodríguez-Part, M. E. Martínez-Corral, et al. “PSA Kinetics and Predictors of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors.” Urologic Oncology, 2025.
R. Postma, Arno G J L H van Leenders, M. Roobol, F. Schröder, and T. H. van der Kwast. “Tumour Features in the Control and Screening Arm of a Randomized Trial of Prostate Cancer.” European Urology, 2006.
R. Stuchbery, G. Macintyre, Marek Cmero, L. Harewood, J. Peters, A. Costello, C. Hovens, and N. Corcoran. “Reduction in Expression of the Benign AR Transcriptome Is a Hallmark of Localised Prostate Cancer Progression.” OncoTarget, 2016.
Richard M Martin, E. Turner, G. Young, C. Metcalfe, E. Walsh, J. Lane, Jonathan A.C. Sterne, et al. “Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.” Journal of the American Medical Association (JAMA), 2024.
S. Akan, Numan Doğu Güner, C. Ediz, A. Şahin, and A. Verit. “Is PSA Still the Best Predictor for Biochemical Recurrence After Radical Prostatectomy in High-Risk Prostate Cancer?” Journal of Investigative Surgery, 2022.
S. Carlsson, A. Maschino, F. Schröder, C. Bangma, E. Steyerberg, T. H. van der Kwast, G. V. van Leenders, A. Vickers, H. Lilja, and M. Roobol. “Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared with Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results from the European Randomized Study of Screening for Prostate Cancer Section Rotterdam.” European Urology, 2013.
S. Malone, S.C. Morgan, D. Spratt, Y. Sun, A.T.T.H. Le, J. Malone, S. Grimes, A. U. Kishan, D. E. Citrin, and S. Roy. “Association of Prostate Specific Antigen Kinetics After Testosterone Recovery with Subsequent Recurrence: Secondary Analysis of a Phase III Randomized Controlled Trial.” International Journal of Radiation Oncology, Biology, Physics, 2023.
S. Maruyama, N. Shinohara, T. Abe, A. Sazawa, and K. Nonomura. “Can PSA Doubling Time Exactly Predict the Candidates for Active Surveillance in Patients with Low-Risk Prostate Cancer?” Journal of Clinical Oncology, 2012.
Shu Wang, J. Kozarek, Ryan F. Russell, Max Drescher, Amir Khan, V. Kundra, K. Barry, M. Naslund, and M. Siddiqui. “Diagnostic Performance of Prostate-Specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.” European Urology Oncology, 2023.
T. Mäkinen, T. Tammela, M. Hakama, U. Stenman, S. Rannikko, J. Aro, H. Juusela, L. Määttänen, and A. Auvinen. “Tumor Characteristics in a Population-Based Prostate Cancer Screening Trial with Prostate-Specific Antigen.” Clinical Cancer Research, 2003.
U. Studer, L. Collette, P. Whelan, W. Albrecht, J. Casselman, T. D. de Reijke, H. Knönagel, et al. “Using PSA to Guide Timing of Androgen Deprivation in Patients with T0-4 N0-2 M0 Prostate Cancer Not Suitable for Local Curative Treatment (EORTC 30891).” European Urology, 2008.
V. Chalasani, and P. Bergersen. “Abstract Journal Urology.” ANZ Journal of Surgery, 2021.
V. J. Valencia-Guadalajara, L. Martínez‐Cayuelas, P. Sarrió-Sanz, L. Sánchez-Caballero, Rebeca Polo-Hernández, F. S. Chillón-Sempere, J. Galán-Llopis, et al. “[Androgen Deprivation Therapy in Advanced Prostate Cancer. Multicenter Study.].” Archivos Españoles de Urología, 2020.
Valentina Orlando, D. Drubay, P. Lavaud, L. Faivre, F. Lesaunier, R. Delva, G. Gravis, et al. “Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.” Clinical Genitourinary Cancer, 2023.
W. Shabana, V. Mehrnoush, Neda Ghaffari-Marandi, K. Dolcetti, H. Elmansy, K. Ramchandar, Edwin Long, A. Zakaria, A. Kotb, and W. Shahrour. “MP53-08 EFFECT OF NEARNESS TO CANCER CENTRE ON PROSTATE CANCER OUTCOMES AND PATIENT'S CHOICE FOR THE TYPE OF INTERVENTION.” Journal of Urology, 2022.
Xiaochuan Wang, Yu Zhang, Z. Ji, Peiqian Yang, and Ye Tian. “Men with High Prostate Specific Antigen Have Higher Risk of Gleason Upgrading After Prostatectomy: A Systematic Review and Meta-Analysis.” Urologia Journal, 2020.
Xiaojie Bian, Weijie Gu, Xuepei Zhang, Li-Yuan Xie, Shaogang Wang, Benkang Shi, Ting Sun, et al. “Correlation of PSA and Survival in Metastatic Hormone-Sensitive Prostate Cancer Treated with Rezvilutamide Plus ADT in the CHART Trial.” I Medicina, 2024.
Y. Ou, Jung‐Ta Chen, Chen-Li Cheng, H. Ho, and Chi-rei Yang. “Radical Prostatectomy for Prostate Cancer Patients with Prostate-Specific Antigen >20 Ng/Ml.” Japanese Journal of Clinical Oncology, 2003.
Yen-Chi Lin, Po-Hung Lin, I. Shao, Y. Chu, Hung-Cheng Kan, Chung-Yi Liu, Kai-Jie Yu, et al. “Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy.” Journal of Oncology, 2021.
Yongming Kang, Pan Song, K. Fang, Bo Yang, Luchen Yang, Jing Zhou, Linchuan Wang, and Q. Dong. “Survival Outcomes of Low Prostate-Specific Antigen Levels and T Stages in Patients with High-Grade Prostate Cancer: A Population-Matched Study.” Journal of Cancer, 2020.
Z. Ayoub, J. Khader, M. Bulbul, R. Khauli, T. Andraos, A. Shamseddine, D. Mukherji, and F. Geara. “Adjusting the Duration of Androgen Deprivation Therapy (ADT) Based on Nadir PSA for High Risk Localized Prostate Cancer Patients Treated with Definitive External Beam Radiation Therapy and ADT.” BMC Urology, 2022.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Brahm Setioesa, Bendy Dwi Irawan, Cita Pakarti Dharma Kusuma (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
